ClinicalTrials.gg
Active, not recruitingNCT05803434CBD_REUpdated Oct 9, 2026

Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy

A Phase 2 interventional study of Cannabidiol oral solution in Epilepsy and Rare Diseases, sponsored by Meyer Children's Hospital IRCCS. Active, not recruiting at 1 site in Italy. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Meyer Children's Hospital IRCCS · Phase 2, Interventional, and Treatment

How we know

Updated Oct 9, 2026Now Active, not recruitingFirst site in Italy+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
2 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing cannabidiol in Epilepsy — 2 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Epilepsy.

Planned enrollment
12th of 20
30 · median 35
Started
2024
the only one that year
Phase 2
6 of 20
none open now
Registered
18th of 20
by date
Lead sponsor
1 of 20
Meyer Children's Hospital IRCCS

Among the 20 studies testing cannabidiol in Epilepsy, this one is the 12th largest by planned enrollment, is the only one that started in 2024, is one of 6 in phase 2, and was the 18th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 20 studies testing cannabidiol in Epilepsy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 2 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing cannabidiol in Epilepsy, or all of them as a file.
02

Study summary

This is a pilot, open-label, phase II study. The main objective of the study is to demonstrate that Cannabidiol (CBD), used in addition to current anti-seizure medications (ASMs) reduces the number and/or severity of motor (generalized, focal, or both) seizures in children and young adults with rare disease-associated severe epilepsy.

Secondary objectives include assessment of safety and tolerability, changes in behaviour, cognition and sleep, pharmacokinetic interaction with concurrent ASMs.

03

Conditions studied

  • Epilepsy
  • Rare Diseases

Keywords

  • drug resistant epilepsy
  • rare epilepsy
  • cannabidiol
04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female;
  2. Children (age 2-18 years) and young adults (18-25 years), as of the day of the Screening Visit;
  3. Subject with rare disease-associated severe epilepsy. Subject has been certified by the National Health System as affected by a rare disease listed in https://www.malattierare.gov.it
  4. Patient has severe epilepsy, with at least 4 motor (generalized, focal, or both) seizures per month during baseline period, despite 2 or more current or prior ASMs;
  5. Previous treatment with at least 2 ASMs;
  6. Currently taking at least 1 other ASMs or between one and four ASMs, with a stable antiseizure treatment for the previous 4 weeks (including ketogenic diet and vagal nerve stimulation);
  7. Subject's parent/caregiver has been informed of the nature of the study and has been obtained from the legally responsible parent/guardian;
  8. Subject's parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability in the opinion of the investigator

Exclusion criteria

Exclusion Criteria:

  1. Age \<2 years;
  2. Known to CBD or any of the in the study formulation;
  3. Progressive neurological disease;
  4. unstable medical conditions other than epilepsy that may place patient's safety at risk;
  5. Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, may influence the result of the study, or affect the patient's ability to participate in the study;
  6. Impaired hepatic function at screening defined as any of the following: (ALT) or aspartate aminotransferase (AST) greater than 3 times the (ULN) and total (TBL) greater than 2 times the ULN;
  7. Subject taking more than four concurrent ASMs;
  8. Subject has taken corticotropins in the six months prior to screening;
  9. Subjects taking felbamate, and they have been taking it for less than one year prior to screening;
  10. Inadequate supervision by parents and/or caregivers as judged by the investigator;
  11. Subject has been part of a clinical trial involving another medicinal product in the previous six months;
  12. Current or past use of recreational or medicinal cannabis, or cannabinoid-based medications, within the three months prior to screening and is unwilling to abstain for the duration for the study;
  13. Female patients who are pregnant;
  14. Female patients of or male patient whose partner is of childbearing potential, unless willing to ensure that they or their partner use a highly effective method of during the study and for three months thereafter.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cannabidiol treatment

    Drug: Cannabidiol oral solution

Interventions

  • DrugCannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response. Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks.

06

What researchers measure

Primary outcomes

  1. Change in number of generalized and/or focal motor-onset seizure frequency

    percentage change per 28 days from the 4-week baseline period in generalized and/or focal motor-onset seizure frequency during the 24-week treatment period

    Time frame: 24 weeks

  2. Change in severity of generalized and/or focal motor-onset seizure frequency

    a score will be established for each patient, based on review and comparison of all baseline-EEG/7-weeks control-EEG and baseline-EEG/15-weeks control-EEG, with values ranging from 0 (= worsened EEG), to a maximum of 2 (= improved); 1 will be assigned if the EEG trace is unmodified

    Time frame: 24 weeks

Secondary outcomes

  1. Incidence of adverse events

    Adverse events reporting according to Common Terminology Criteria for Adverse Events (CTCAE) from 1 (mild) to 5 (death)

    Time frame: 24 weeks

  2. Body weight

    Measurement of body weight for tolerability monitoring

    Time frame: 24 weeks

  3. Maximum Plasma Concentraion [Cmax] of concurrent ASMs

    blood levels of concurrent ASMs will be taken at baseline and every 4 weeks

    Time frame: 24 weeks

  4. Number of subjects considered treatment responders

    Number of subjects with a ≥25%, ≥50% ≥75% reduction in motor (generalized, focal, or both) seizures from baseline

    Time frame: 24 weeks

  5. Number of subjects who are free of motor (generalized, focal, or both) seizures

    Number of subjects who are free of motor (generalized, focal, or both) seizures

    Time frame: 24 weeks

  6. Longest period of seizure freedom

    Longest period of seizure freedom

    Time frame: 24 weeks

  7. Number of patients experiencing a >25% worsening, -25 to +25% no change, 25-50% improvement, 50-75% improvement or >75% improvement in total seizures from baseline

    Number of patients experiencing a \>25% worsening, -25 to +25% no change, 25-50% improvement, 50-75% improvement or \>75% improvement in total seizures from baseline

    Time frame: 24 weeks

  8. Changes from baseline in number of inpatient hospitalizations due to epilepsy

    Changes from baseline in number of inpatient hospitalizations due to epilepsy

    Time frame: 24 weeks

  9. Change in severity of seizures will be assessed using a pediatric adaptation of the Chalfont Seizure Severity Scale

    Change in severity of seizures will be assessed using a pediatric adaptation of the Chalfont Seizure Severity Scale (from 1 minimum severity to \>100 max severity)

    Time frame: 24 weeks

  10. Change from baseline to 6-months after treatment initiation in number of seizure-free days

    Change from baseline to 6-months after treatment initiation in number of seizure-free days

    Time frame: 24 weeks

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Apr 2026, 24 months.

Of 67 phase 2 interventional studies under Epilepsy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 24 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jun 2023 → Mar 2024, primary completion Mar 2025 → Apr 2026 and completion Mar 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Apr 7, 2023
StartActual
Mar 14, 2024was Jun 2023
Primary completionActual
Apr 1, 2026was Mar 2025
CompletionEst.
Dec 1, 2026was Mar 2025
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Active, not recruiting
changed Oct 9, 2026
Sites
1 site added — first site in Italy
Show site
  • Meyer Children's Hospital IRCCS · Florence, Italy
Oct 9, 2026
Start date
Jun 1, 2023→Mar 14, 2024 (actual)
Oct 9, 2026
Primary completion
Mar 1, 2025→Apr 1, 2026 (actual)
Oct 9, 2026
Study completion
Mar 1, 2025→Dec 1, 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Status unknown→Active, not recruiting
    1 site added — first site in Italy
    Show site
    • Meyer Children's Hospital IRCCS · Florence, Italy
    Start date Jun 1, 2023→Mar 14, 2024 (now actual)
    Primary completion Mar 1, 2025→Apr 1, 2026 (now actual)
    Study completion Mar 1, 2025→Dec 1, 2026
    + 4 other changes: verification date, responsible party, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05803434
Lead sponsor
Meyer Children's Hospital IRCCS
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Mar 14, 2024
Primary completion
Apr 1, 2026
Completion
Dec 1, 2026 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion